INTRODUCTION: The aim of this study was to provide detailed age-specific (5-year age groups) and histology-specific (histologic subtypes of seminoma and nonseminoma) relative survival estimates of testicular germ cell cancer patients in Germany and the United States (U.S.) for the years 2002-2006 and to compare these estimates between countries. METHODS: We pooled data from 11 cancer registries of Germany and used data from the U.S. (SEER-13 database) including 11,508 and 10,774 newly diagnosed cases (1997-2006) in Germany and the U.S., respectively. We estimated 5-year relative survival (5-year-RS) by histology and age based on period analysis. RESULTS: 5-year-RS for testicular germ cell tumors was 96.7% and 96.3% in Germany and the U.S., respectively. 5-Year-RS for spermatocytic seminoma was close to 100% in both countries. 5-Year-RS for nonseminoma was lower than for classical seminoma in Germany (93.3% versus 97.6%) and the U.S. (91.0% versus 98.2%). Among nonseminomas, choriocarcinomas provided the lowest 5-year-RS in both countries (Germany 80.1%, U.S. 79.6%). Age-specific 5-year-RS for seminoma showed only little variation by age. 5-Year-RS for nonseminomas tended to be lower at higher ages, especially for malignant teratoma. DISCUSSION: This is the first study that provides up-to-date survival estimates for testicular cancer by histology and age in Germany and the U.S. Survival after a diagnosis of testicular cancer is very comparable between Germany and the U.S. 5-Year-RS for spermatocytic seminoma was close to 100% and the lowest 5-year-RS occurred among choriocarcinoma. Higher age at diagnosis is associated with a poorer prognosis among nonseminoma patients.
INTRODUCTION: The aim of this study was to provide detailed age-specific (5-year age groups) and histology-specific (histologic subtypes of seminoma and nonseminoma) relative survival estimates of testicular germ cell cancerpatients in Germany and the United States (U.S.) for the years 2002-2006 and to compare these estimates between countries. METHODS: We pooled data from 11 cancer registries of Germany and used data from the U.S. (SEER-13 database) including 11,508 and 10,774 newly diagnosed cases (1997-2006) in Germany and the U.S., respectively. We estimated 5-year relative survival (5-year-RS) by histology and age based on period analysis. RESULTS: 5-year-RS for testicular germ cell tumors was 96.7% and 96.3% in Germany and the U.S., respectively. 5-Year-RS for spermatocytic seminoma was close to 100% in both countries. 5-Year-RS for nonseminoma was lower than for classical seminoma in Germany (93.3% versus 97.6%) and the U.S. (91.0% versus 98.2%). Among nonseminomas, choriocarcinomas provided the lowest 5-year-RS in both countries (Germany 80.1%, U.S. 79.6%). Age-specific 5-year-RS for seminoma showed only little variation by age. 5-Year-RS for nonseminomas tended to be lower at higher ages, especially for malignant teratoma. DISCUSSION: This is the first study that provides up-to-date survival estimates for testicular cancer by histology and age in Germany and the U.S. Survival after a diagnosis of testicular cancer is very comparable between Germany and the U.S. 5-Year-RS for spermatocytic seminoma was close to 100% and the lowest 5-year-RS occurred among choriocarcinoma. Higher age at diagnosis is associated with a poorer prognosis among nonseminoma patients.
Authors: M Sant; R Capocaccia; M P Coleman; F Berrino; G Gatta; A Micheli; A Verdecchia; J Faivre; T Hakulinen; J W Coebergh; C Martinez-Garcia; D Forman; A Zappone Journal: Eur J Cancer Date: 2001-09 Impact factor: 9.162
Authors: M P Coleman; G Gatta; A Verdecchia; J Estève; M Sant; H Storm; C Allemani; L Ciccolallo; M Santaquilani; F Berrino Journal: Ann Oncol Date: 2003 Impact factor: 32.976
Authors: E Hiripi; A Gondos; K Emrich; B Holleczek; A Katalinic; S Luttmann; E Sirri; H Brenner Journal: Ann Oncol Date: 2011-05-19 Impact factor: 32.976
Authors: Katarina Kalavska; Zuzana Sestakova; Andrea Mlcakova; Paulina Gronesova; Viera Miskovska; Katarina Rejlekova; Daniela Svetlovska; Zuzana Sycova-Mila; Jana Obertova; Patrik Palacka; Jozef Mardiak; Miroslav Chovanec; Michal Chovanec; Michal Mego Journal: Life (Basel) Date: 2022-05-02
Authors: Hui Shen; Juliann Shih; Daniel P Hollern; Linghua Wang; Reanne Bowlby; Satish K Tickoo; Vésteinn Thorsson; Andrew J Mungall; Yulia Newton; Apurva M Hegde; Joshua Armenia; Francisco Sánchez-Vega; John Pluta; Louise C Pyle; Rohit Mehra; Victor E Reuter; Guilherme Godoy; Jeffrey Jones; Carl S Shelley; Darren R Feldman; Daniel O Vidal; Davor Lessel; Tomislav Kulis; Flavio M Cárcano; Kristen M Leraas; Tara M Lichtenberg; Denise Brooks; Andrew D Cherniack; Juok Cho; David I Heiman; Katayoon Kasaian; Minwei Liu; Michael S Noble; Liu Xi; Hailei Zhang; Wanding Zhou; Jean C ZenKlusen; Carolyn M Hutter; Ina Felau; Jiashan Zhang; Nikolaus Schultz; Gad Getz; Matthew Meyerson; Joshua M Stuart; Rehan Akbani; David A Wheeler; Peter W Laird; Katherine L Nathanson; Victoria K Cortessis; Katherine A Hoadley Journal: Cell Rep Date: 2018-06-12 Impact factor: 9.423